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Background: The screening of BRCA1 and BRCA2 mutations is now an established component of risk evaluation
and management of familial breast cancer, early-onset breast cancer and bilateral breast cancer patients. There is
still some controversy about whether this screening should be done in triple-negative breast cancers. Therefore, we
evaluated the BRCA mutation prevalence in patients with triple-negative breast cancer in a multi-ethnic region of
China.
Methods: A total 96 women who were diagnosed with triple-negative breast cancer in the Xinjiang region of China
were enrolled in this study. BRCA1 and BRCA2 screening was performed by polymerase chain reaction-denaturing
high-performance liquid chromatography (PCR-DHPLC) sequencing analysis. All mutations were confirmed with
direct sequencing.
Results: The prevalence of a BRCA1/2 germline mutation was about 25% (24/96) in the Xinjiang region of China.
Among 35 selected cases with a family history and/or bilateral breast cancers, the BRCA1/2 mutation prevalence
was 25.7% (9/35). Of the remaining 61 patients with unselected triple-negative breast cancer, the BRCA1/2 mutation
prevalence was 24.6% (15/61), and all 15 individuals with these mutations were premenopausal patients.
Conclusions: These results suggest that premenopausal women with triple-negative breast cancer may be
candidates for genetic testing for BRCA1/2 in the Xinjiang region of China, even in the absence of a family
history or bilateral breast cancer.
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The two major contributors to hereditary breast cancer
are the breast cancer susceptibility gene 1 (BRCA1) and
BRCA2 [1]. Genetic testing for BRCA1 and BRCA2 mu-
tations has been established throughout North America
and most of Europe. Not all women are candidates for
testing; in general, testing is only necessary for women
who have a familial breast cancer, early-onset breast can-
cer or bilateral breast cancer.
China is a multi-ethnic country, but the majority of
the population belongs to the Han ethnic group. Chinese
breast cancer patients on average were younger than pa-
tients in America and Europe by about 10 years old, and* Correspondence: oujianghua@hotmail.com
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unless otherwise stated.premenopausal patients accounted for the majority [2].
The prevalence of BRCA1 and BRCA2 mutations among
the Chinese Han population was less than 20%, mutation
of BRCA2 gene was higher than that of BRCA1 [3,4],
and this is significantly different than for America and
Europe populations [5].
To date, only a few studies have been reported on
BRCA-associated breast cancer in China; all the studies
involved mainly ethnic Han Chinese. Our previous study
showed that the prevalence of the BRCA1/2 germline
mutation was about 7.6% (6/79) in the Xinjiang multi-
ethnic region of China. Among six of these BRCA-related
tumors, three BRCA1- and one BRCA2-associated tu-
mors were in estrogen receptor (ER), progesterone re-
ceptor (PR) and human epidermal growth factor receptor
2 (HER-2) triple-negative status [6].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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group of tumors that lack expression of ER, PR and
HER-2. Due to the lack of effective targets for endocrinal
and molecular treatment, it is considered a type of high
risk breast cancer, and the prognosis is poor. Overall,
TNBC accounts for about 15% [7,8] of all breast cancers,
but occurs more frequently in younger women and is
the predominant subtype in individuals with a germline
BRCA1 mutation [9]. Therefore, we have evaluated the
BRCA mutation frequency and the implications for the




All patient cases were recruited from Xinjiang, China.
They had a definite pathological diagnosis of breast can-
cer and received the standard treatment in our hospital
during the period 2005 to 2013. At the beginning of this
period, women diagnosed with breast cancer who had
family history (FH), early onset, or bilateral breast cancer
(BI-BC) were chosen for study. As the research developed,
we found that the majority of patients with the BRCA1/2
germline mutation were in triple-negative status. There-
fore, TNBC patients were included in our study. To date,
a total of 214 patients were submitted for evaluation, of
which 96 were TNBC.
The study was approved by the Ethics Committee (IRB
approval number: XJYD1320) of the Cancer Hospital of
Xinjiang Medical University, and informed consent was
obtained from each participant.
Triple-negative breast cancer confirmed
ER, PR and HER-2 status were confirmed in a histopath-
ology report of the tumor samples. HER-2 was regarded
as negative when scored as 0 or 1 by immunohistochemis-
try (IHC) and/or when there was non-amplification of
HER-2 mRNA by fluorescent in situ hybridization (FISH).
BRCA1/2 mutation analysis
Genomic DNA was isolated from 5 mL of peripheral
blood and stored in 10 mM Tris (pH 8) EDTA at 4°C.
Specific BRCA1 and BRCA2 coding regions and intron-
exon boundaries, ranging from 206 to 639 bp in length,
were amplified by polymerase chain reaction (PCR).
Denaturing high-performance liquid chromatography
(DHPLC) analysis was used to screen BRCA1 and BRCA2
mutations; all variants identified were confirmed by direct
sequencing.
Statistical analysis
To compare the BRCA1/2 mutation in unselected and
selected TNBC, chi-square analysis was performed. A
P value of <0.05 was considered statistically significant.The SPSS statistical software system version 16.0 (SPSS
Inc., Chicago, USA) was used.
Results
Patients’ characteristics
A total of 96 women with TNBC were eligible for testing.
Among them, 35 women were selected for study because
they had FH and/or BI-BC (25 women had a FH of breast
or ovarian cancer, 13 women were BI-BC, both a FH and
BI-BC were identified in 3 women). The remaining 61 pa-
tients had unselected TNBC. The average age of the pa-
tients was 39.7 years old (range 24 to 64 years old).
BRCA1/2 mutations
The full results of all BRCA1/2 deleterious mutations
are given in Additional file 1: Table S1, all mutations
were protein-truncating. Both the BRCA1 and BRCA2
mutation was identified in one patient with a family his-
tory, and she was 47 years old. BRCA1/2 mutations were
present in 24 out of 96 individuals with TNBC. The preva-
lence of the BRCA1/2 germline mutation was about 25%
(24/96), 18 in BRCA1 and 7 in BRCA2 (Table 1). The
prevalence of BRCA1 germline mutation was about 18.6%
(18/96), and the prevalence of BRCA2 germline mutation
was about 7.3% (7/96).
Eighty-one of the 96 women were premenopausal pa-
tients, The BRCA1/2 mutation prevalence was about
27.2% (22/81); among them, BRCA1 mutation prevalence
was about 19.8% (16/81), and BRCA2 mutation prevalence
was about 8.6% (7/81). The remaining 15 cases were post-
menopausal patients, the BRCA1/2 mutation prevalence
was about 13.3% (2/15), the BRCA1 mutation prevalence
was about 13.3% (2/15), and BRCA2 had no mutation. If
we remove the 35 cases with family history and/or bilat-
eral breast cancers from the analysis, a total of 15 (24.6%)
BRCA1/2 mutations were identified in the remaining 61
patients of unselected triple-negative breast cancer. All
mutations in 15 individuals were premenopausal patients.
Among the 15 patients, 11 (18%, 11/61) had BRCA1 mu-
tations, and 4 (6.6%, 4/61) had BRCA2 mutations. There-
fore, the prevalence of BRCA1 mutations is greater than
the prevalence of BRCA2 in TNBC patients.
A total of 18 BRCA1 mutations were identified; 13 of
these mutations (72.2%) were in exons 10 and 11. Eight
BRCA2 mutations were identified; six mutations among
them (75%) were in exons 10 and 11.
Comparison of BRCA1/2 mutation between unselected
and selected triple-negative breast cancer
A total of 96 women with TNBC were analyzed: 35 cases
were selected TNBC (25 women had FH of breast or
ovarian cancer, 13 women had BI-BC, and 3 women had
a FH and had BI-BC) and 61 cases were unselected TN
cancers. A total of 7 (28%) mutations were identified in
Table 1 BRCA1 and BRCA2 mutation prevalence in premenopausal/postmenopausal triple-negative breast cancer
(TNBC) patients
Number of cases BRCA1 mutations (%) BRCA2 mutations (%) Total BRCA1/2 mutations (%)
All 96 18 (18.6) 7 (7.3) 24 (25)a
Premenopausal 81 16 (19.8) 7 (8.6) 22 (27.2)a
Postmenopausal 15 2 (13.3) 0 2 (13.3)
All unselected TNBC 61 11 (18) 4 (6.6) 15 (24.6)
Premenopausal 55 11 (20) 4 (7.3) 15 (27.3)
Postmenopausal 6 0 0 0
aBoth BRCA1 and BRCA2 mutations were identified in one patient with family history, and she was 47 years old.
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tions were identified in 13 patients who had bilateral
breast cancer, and 15 (24.6) mutations were identified in
61 patients who had unselected TNBC (Table 2). A com-
parison of the three kinds of patients by chi-square test
showed no significant difference (P = 0.687).
A total of 9 (25.7%) BRCA1 and BRCA2 mutations
were identified in 35 selected patients, and 15 (24.65)
BRCA1 and BRCA2 mutations were identified in the 61
unselected patients (Table 3). It makes no difference in
the prevalence ofTNBC whether the BRCA1/2 mutation
is selected or not. When all 96 TNBC were broken down
into different age groups, BRCA1 and BRCA2 mutations
were 25% (5/20) in unselected women with TNBC ≤ 35
years old and 33.3% (2/6) in women with a FH and/or
BI-BC, TNBC and ≤ 35 years old.
Discussion
These data support the position that premenopausal
TNBC is an indicator that can be used to help to identify
candidates for BRCA1/2 mutation testing. BRCA1/2
germline mutations are responsible for genetic predis-
position and may increase the risk for breast and ovarian
cancer [1]. The prevalence of BRCA mutations varies
among different populations due to founder mutation ef-
fects and environmental factors [10,11]. Genetic cancer
risk assessment guideline and genetic testing for breast
cancer have become standard clinical management for
selected patients in Western populations. But theTable 2 BRCA1/2 mutation prevalence in the unselected
and selected triple-negative breast cancer (TNBC)
patients
Cases classification BRCA1/2 Mutation χ2 p
Yes (%) No
Family history 7 (28) 18 0.752 0.687a
Bilateral breast cancer 2 (15.4) 11
Triple-negative 15 (24.6) 46
aThere was no significant difference among the three kinds of patients (TNBC
with family history, TN cancers with bilateralbreast cancer and single TNBC)
(P >0.05).situation in China is less managed. Only a few of
studies reported BRCA mutations among breast can-
cer patients in China; the subjects were mainly famil-
ial breast cancer, early-onset breast cancer and
bilateral breast cancer. Based on these studies, the
BRCA mutation rate is generally less than 20% in
China [3,4,12]. Our data show the prevalence of the
BRCA1/2 mutation in 96 cases of TNBC was 25%,
close to the previous studies.
TNBC is a subgroup of breast tumors with poor prog-
nosis. TNBCs are the predominant cancer subtype with
a germline BRCA mutation. The prevalence of the BRCA
mutation was 10 to 30% [13-15]. A total of 15 (24.6%)
mutations were identified in 61 patients who had unse-
lected TNBC (Table 3). The frequency of unselected
TNBC is similar to the frequency of BRCA1/2 mutations
in individuals that were selected for inclusion because of
a family history or bilateral breast cancer. Our study in-
cluded samples of unselected TN cancers, which were
primarily diagnosedin premenopause; only six cases were
postmenopausal. All mutations were found in premeno-
pausal patients. The prevalence of the BRCA1 germline
mutation was about 18.6% (18/96), and the prevalence
of the BRCA2 germline mutation was about 6.3% (6/96).
Prevalence of BRCA1 mutations is more common than
BRCA2 in TNBC patients, and BRCA1 mutation is
mainly associated with TNBC. All the BRCA1 mutations
are in TNBC cases with higher histological grades of in-
vasive ductal carcinoma. These findings coincided with
earlier findings for Asian populations, including Chinese
[3,10-12], where BRCA1-mutated tumors conferred the
following features: they were ER- or PR-negative and
had a higher histological grade, but exhibited less medul-
lary carcinoma compared to the Western population
[16]. Whereas about 70% of the patients from this earlier
study of TNBC in China were premenopausal [17], in
our study, all BRCA mutations in TNBC were in pre-
menopausal patients. TNBC with family history may in-
fluence the BRCA mutation; when the 96 TNBCs were
broken down into different age groups, BRCA1 and
BRCA2 mutations were 25% (5/20) in unselected women
(≤ 35 years old) with TNBC and 33.3% (2/6) were in
Table 3 BRCA1/2 mutation prevalence in unselected/selected triple-negative breast cancer (TNBC) patients
Number of cases BRCA1 mutations (%) BRCA2 mutations (%) Total BRCA1/2 mutations (%)
All selected TN 35 7 (20) 3 (8.6) 9 (25.7)
< 35 years 6 1 (16.7) 1 (16.7) 2 (33.3)
≥ 35 years 29 6 (20.7) 2 (6.9) 7 (24.1)a
All unselected TN 61 11 (18) 4 (6.6) 15 (24.6)
< 35 years 20 4 (20) 1 (5) 5 (25)
≥ 35 years 41 7 (17.1) 3 (7.3) 10 (24.4)
Selection criteria: Selected = bilateral breast cancer and/or family history of TNBC; Unselected = TNBC.
aBoth BRCA1 and BRCA2 mutations were identified in one patient with family history, and she was 47 years old.
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respectively. These results are consistent with those re-
ported in [18]. Although this study is not a large-scale
investigation (only 96 patients), our results suggest that
diagnosis of premenopausal TNBC would be a suitable
threshold for BRCA testing. It is also consistent with
simulation data, suggesting that this testing threshold
would be a cost-effective strategy [19].
China is a developing country with multiple ethnic
groups. Due to variations in the breast cancer prevalence,
molecular subtypes and onset age among the different
races and ethnicities, and because BRCA mutations are
also different, caution must be exercised when following
the clinical guidelines of the genetic and high familial risk
assessment of breast cancer in the The National Compre-
hensive Cancer Network (NCCN) data. Most of those data
come from Western populations, and in China, genetic
testing should be modified to better assess the Chinese
population. Our study only provides some preliminary in-
formation of BRCA mutation of TNBC in the multi-
ethnic region of Xinjiang, China. Our dataset is relatively
small, but we confirmed similar observations made by
others. To date, no single study has been large or defini-
tive in China for TNBC BRCA mutations, and therefore,
it is important to consider the results of all studies in ag-
gregate. More precise figures would be obtainable from
larger, prospective studies. We also found a number of po-
tential BRCA mutation hotspot regions in Xinjiang TNBC
patients, such as the mutation mainly in exons 10 and 11,
but our conclusions need further study and more data
collection.
Conclusions
Premenopausal women with TNBC may be candidates
for genetic testing for BRCA1/2 in the Xinjiang region of
China, even in the absence of a family history or bilateral
breast cancer.
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